Tag: CSL – Seqirus
Australia extends life-saving antivenom partnership with PNG
Australia is bolstering its support for Papua New Guinea's health system by renewing its partnership, which includes supplying antivenom doses and training healthcare workers, for an additional three years until 2027.
CSL’s $800 million vaccine manufacturing facility in Melbourne nears completion
CSL Seqirus has reached a major milestone in the construction of its new cutting-edge manufacturing facility for vaccine and antivenom manufacturing.Â
TGA approves domestic manufacture of AstraZeneca vaccine
CSL has been given the nod by the Therapeutic Goods Administration (TGA) to commence the manufacture of the AstraZeneca COVID-19 Vaccine (ChAdOx1-S) in Australia.
TGA’s...
Featured Article
Unlocking growth: Charting midsize manufacturers’ path with digital solutions
According to a recent study by Oxford Economics, midsized companies in the industrial manufacturing sector are setting their eyes on ambitious growth targets. The research, authored in partnership with SAP, revealed that 38% of industry leaders have identified market expansion as their top priority.
